Slovakia: Medical and Donor Requirements for Surrogacy
The short answer: separate legality from medical screening
As of 21 October 2026, the first question is not whether a carrier or gamete donor passes a medical screen. Slovakia’s Constitution now states: “An agreement to give birth to a child for another is prohibited.” Constitutional Act No. 255/2025 Coll. took effect on 1 November 2025. The Family Act separately provides that the mother is the woman who gave birth and that agreements or contracts contrary to that rule are invalid. These rules make a planned surrogacy agreement a legal stop point, not a problem that can be solved by a clinic’s medical approval.
This guide separates three questions: the legal boundary for a surrogacy agreement; statutory safeguards for donor reproductive cells used in assisted reproduction; and medical protocols set by a clinic. Donor-screening rules are real legal requirements, but they do not create an exception to the constitutional ban. It does not decide every possible procedure or cross-border fact pattern.
1. The binding legal boundary in Slovakia
Article 15(5) of the Slovak Constitution, added by Constitutional Act No. 255/2025 Coll., says: “An agreement to give birth to a child for another is prohibited.” The amendment’s Article II sets its effective date as 1 November 2025. This is a binding constitutional rule, not a clinic recommendation or an industry standard.
Section 82(1) of the Family Act, Act No. 36/2005 Coll., says that the mother is the woman who gave birth to the child. Section 82(2) makes agreements and contracts contrary to that rule invalid. Read together, these provisions mean that parties should not assume a contract can require a woman to relinquish legal motherhood or make intended parents the legal parents by contract alone.
The constitutional clause itself does not set out a separate criminal offence, penalty schedule, clinical checklist or detailed transitional procedure. Do not invent one, and do not jump from the agreement ban to a claim that every assisted-reproduction treatment or every act involving gametes is prohibited. The precise consequences for a proposed clinical protocol, a process begun earlier, or a cross-border arrangement require advice from Slovak counsel and a current check of implementing law. The safe conclusion is narrower but decisive: do not sign, fund or present a Slovak surrogacy agreement as lawful or enforceable without specific legal advice.
2. Why medical eligibility cannot cure the legal problem
Medical fitness and legal permission are different tests. A healthy woman, an uncomplicated obstetric history, favourable laboratory results, a diagnosis of infertility in the intended parent, use of the intended parent’s own egg or sperm, use of donor gametes, an altruistic arrangement or the absence of a fee does not, by itself, displace the constitutional wording. The cited constitutional clause contains no express exception for those facts, and the cited statutes do not establish a surrogacy-specific medical eligibility route that overrides it.
This does not mean that all IVF or donor conception is prohibited. Act No. 317/2016 Coll. expressly regulates reproductive human cells, and ordinary fertility treatment may be considered under its own legal and clinical rules. But a clinic’s willingness to accept a patient, approve an embryo transfer or advertise a service is not a legal ruling that a planned surrogacy agreement is valid. Analyse the legality of the arrangement first; consider medical suitability for any independently lawful treatment second.
3. What the general healthcare law requires
Section 6 of Act No. 576/2004 Coll. requires a healthcare professional to explain the purpose, nature, consequences and risks of care, the available options and the risks of refusing the proposed care. Written informed consent is required in specified situations, including before invasive procedures under general or local anaesthesia and when a diagnostic or treatment procedure is changed in a way not covered by the earlier consent. Consent may be withdrawn freely. The precise statutory conditions should be checked against the current text and the procedure actually proposed.
This general consent regime does not create a right to every assisted-reproduction method and does not validate a surrogacy agreement. Nor should one assume that Slovak legislation sets a single universal age, BMI, AMH or ovarian-reserve threshold, uterine-scan result, embryo-transfer limit, psychological-assessment rule or carrier pregnancy-history requirement. If a clinic quotes a cutoff, ask whether it comes from legislation, regulator or professional guidance, evidence-based clinical judgment, an insurer, or the clinic’s own protocol. Clinical rules may be important, but they should not be mislabelled as statutory surrogacy requirements without a legal source.
4. Statutory donor selection for reproductive cells
Act No. 317/2016 Coll. expressly includes reproductive human cells. For gametes from a person other than the recipient’s partner, § 22(3) requires compliance with donor-selection criteria in Annex 3, Part A, and laboratory testing under Annex 5, Part B. Under § 16, the designated doctor evaluates and documents suitability; the collection organisation gathers medical and behavioural history and relevant records, and at least one interview is conducted with a living donor. Selection is risk-based and may involve physical examination and further appropriate tests. These are legal safeguards for non-partner donor gametes, not permission to arrange a surrogacy birth.
When Annex 3 Part A applies, its general exclusion criteria for living cell donors include unexplained illness; current or past malignancy (subject to listed exceptions and case-specific assessment); uncontrolled systemic infection at the time of donation; a history or clinical/laboratory evidence of HIV or acute/chronic hepatitis B or C (with the Annex’s qualifications); HTLV transmission risk; certain chronic systemic autoimmune diseases that could affect cell quality; and other transmission risks indicated by travel or exposure history, physical signs, or toxic exposure. The Annex also addresses potentially unreliable test results linked to blood-sample dilution or immunosuppressive treatment, recent live-attenuated vaccination where transmission risk is relevant, and prior xenotransplantation. The Annex also includes prion-transmission risks, such as specified Creutzfeldt–Jakob disease histories, rapidly progressive dementia or degenerative neurological disease, certain pituitary-hormone or tissue-transplant exposures, and undocumented neurosurgery. This is a non-exhaustive summary; match the exact criterion and any exception to the donor and cell type.
Section 16(5) also provides a specific decision route: if a donor fails a selection criterion and is excluded, the professional representative of the tissue establishment may nevertheless decide to accept that donor on the basis of a documented risk assessment. This is discretionary, not automatic, and does not by itself waive separate statutory laboratory tests. Ask the clinic whether it relies on § 16(5), who made the decision, and where the written risk assessment is recorded.
Do not transfer the partner-donation exception to an unrelated or non-partner donor. Under § 22(1), the Annex 3 selection criteria and Annex 5, Part B blood tests are not obligatory for partner reproductive cells intended for direct use. If partner cells are not intended for direct use, § 22(2) requires the criteria and tests. The distinction depends on the actual donation, processing, storage and intended-use pathway. Ask the clinic to identify the statutory category it is using and record the reason.
5. Mandatory and risk-triggered donor tests
For non-partner reproductive-cell donation, the statutory blood-test panel includes HIV-1 and HIV-2; hepatitis B (HBsAg and anti-HBc); hepatitis C (anti-HCV antibodies); and syphilis, assessed using a validated testing algorithm. The Annex also requires a negative urine chlamydia test using nucleic-acid amplification (NAT) for a sperm donor. For gametes from a non-partner donor, a blood sample is collected and tested at each donation. The applicable details are in § 22 and Annex 5, Part B, of Act No. 317/2016 Coll.
Section 22(1)’s direct-use partner exception is worded for selection criteria and tests of a blood sample; it does not expressly mention this separate urine test. Do not assume the urine test is waived without a written legal basis.
For syphilis, Annex 5 Part B uses a validated testing algorithm. A reactive non-specific test does not by itself bar collection or use if the specific Treponema pallidum test is non-reactive; a reactive specific test requires a detailed risk assessment to determine suitability.
HTLV-I antibody testing is required if the donor lives in or comes from an area with high HTLV-I prevalence, has a sexual partner from such an area, or the donor’s parents come from such an area. Additional tests may be required depending on travel and exposure history and the cells involved; the statute gives malaria, RhD, CMV and Trypanosoma cruzi as examples. This is a statutory baseline plus risk-triggered testing, not a claim that every donor must undergo every conceivable test. Ask for dated laboratory results and the clinical explanation for any additional test, exclusion or proposed exception.
6. Quarantine, repeat testing and narrow exceptions
Sperm from a non-partner donor must be quarantined for at least 180 days and retested. Annex 5, Part B, provides an exception to repeat testing where an additional donor blood sample is tested by NAT for HIV, HBV and HCV, or the processing includes a validated inactivation step for the relevant viruses. A clinic relying on an exception should identify the precise legal route and show that its conditions are met; a brochure or a general statement that the donor was screened is not enough.
The 180-day rule is sperm-specific; do not copy it onto every egg donation or every reproductive-cell pathway. For partner reproductive cells not intended for direct use, the blood sample for laboratory tests must be collected no more than three months before the first donation. For repeat donations from the same partner, the result remains valid for up to 24 months. A further narrow exception applies in partner donation where sperm is described by the statute as not intended for direct use, is processed for intrauterine insemination and is not intended for storage, provided the collection organisation demonstrates that validated procedures control the risks of cross-contamination and staff exposure. Because the statutory wording is technical, ask the clinic to identify the exact pathway rather than describing it as a general waiver.
For partner reproductive cells not intended for direct use, separate storage is required if test results for HIV-1, HIV-2, hepatitis B or hepatitis C are positive or unavailable, or if the donor is known to present an infectious risk.
These exceptions are technical and fact-dependent. They do not create a general waiver from medical judgment, informed consent, privacy or traceability obligations, and they do not create an exception to the constitutional prohibition on an agreement to give birth for another.
7. Genetic risk, consent, privacy and records
Section 22(6) requires genetic testing for autosomal-recessive genes known, on international scientific knowledge, to be prevalent in the donor’s ethnic profile, and assessment of risks from inherited conditions known in close relatives, after the recipient’s consent. The treating physician must clearly and fully explain the resulting risks and measures that could reduce them. This does not mean that one particular consumer DNA panel is mandatory in every case: the statutory trigger, the test chosen and the counselling should be documented.
For partner-donation cases, § 15(3) requires the donor’s written informed consent to cover the purpose of use and the possibility that unused reproductive cells may be used for other reproductive purposes, research or destruction. Section 3(9) generally requires anonymity between the donor and recipient, including their close persons, and protection of personal data. The Act also provides for traceability and records for reproductive cells. Do not infer from the anonymity clause alone a complete answer about a future child’s access to donor-origin information; that question needs a separate check of the applicable law and current interpretation.
8. Binding law versus clinic policy: a practical matrix
Use the following distinction when a clinic or agency gives you a list of “requirements.” The legal basis and the practical effect are not the same thing. The table summarises the provisions; it is not a substitute for checking the exact procedure and current consolidated law.
| Issue | What the reviewed law establishes | How to treat a clinic statement |
|---|---|---|
| Agreement to give birth for another | The Constitution prohibits the agreement from 1 November 2025; Family Act § 82 protects the birth mother’s legal status and invalidates contrary agreements. | A medical clearance, genetic link or no-fee label does not make the agreement safe or enforceable. Obtain Slovak legal advice before any commitment. |
| Non-partner donor screening | Statutory donor-selection criteria and specified laboratory tests apply, subject to the narrow rules and exceptions in Act No. 317/2016 Coll. | Request the donor category, dated test results, quarantine/retesting record and legal basis for any exception. |
| Patient information and consent | Healthcare law requires information about risks and options and written consent in specified cases. | Read the consent form and ask which procedure it authorises; consent does not validate a prohibited arrangement. |
| Age, BMI, AMH, uterine scans, embryo number or psychological assessment | The cited provisions do not establish a surrogacy-specific statutory checklist for these items. | These may be clinical judgments, professional guidance or clinic-policy thresholds. Ask for the written protocol and its basis; do not call it a statutory rule without a citation. |
| Clinic acceptance, price, insurance or advertised availability | A clinic’s commercial or operational position is not a source of legal permission. | Verify the provider’s authority and the applicable law independently. A service listing is not proof that a surrogacy agreement is lawful. |
9. What to do before booking or signing
A practical review should answer the legal question before you spend money on medical screening. Keep the following steps in order:
- Describe the planned arrangement in one sentence. If it involves a woman agreeing to give birth for another person, treat the constitutional prohibition as a stop point and obtain advice from a Slovak lawyer before signing, paying or starting a protocol designed around that agreement.
- Ask the clinic to name the exact procedure it proposes and identify the statutory basis for it. Do not rely only on an agency brochure, marketing page, verbal assurance or a general statement that “surrogacy is possible.”
- Request a written checklist that labels each item as binding legislation, regulator or professional guidance, evidence-based clinical judgment, insurer requirement or clinic policy. For every item presented as law, ask for the act, section and current version.
- If the case is ordinary assisted reproduction that is independently lawful, request the donor category, screening panel, dates of samples and results, sperm quarantine and repeat-testing records, any claimed exception, genetic-risk counselling, consent forms and traceability/privacy information.
- Keep copies of medical reports, consent forms, proposed contracts, invoices, emails and the clinic’s written legal explanation. Do not treat a favourable medical report as proof that the arrangement is lawful or that parentage is guaranteed.
- If any participant, treatment or birth crosses a border, get separate advice on each relevant country’s law. A foreign clinic’s licence, a foreign birth record or another country’s permissive rules do not by themselves resolve the validity of an agreement under Slovak law.
Primary legal sources
- Constitutional Act No. 255/2025 Coll. (official legally binding PDF)
- Family Act No. 36/2005 Coll. (version effective 1 September 2026)
- Act No. 317/2016 Coll. (official legally binding PDF; version effective 1 September 2023)
- Act No. 576/2004 Coll. (healthcare and informed consent; version effective 1 August 2026)
- Annex 3 to Act No. 317/2016 Coll. (official donor-selection criteria attachment)
Source-version note: the Slov-Lex portal displayed Act No. 317/2016 Coll.
